Imextor 500 Tablet contains Imeglimin 500 mg, an oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin is a novel tetrahydrotriazine compound that improves glycemic control by targeting mitochondrial bioenergetics, enhancing insulin sensitivity, and promoting glucose-dependent insulin secretion. It acts through a dual mechanism involving the reduction of hepatic glucose production and the improvement of peripheral glucose uptake, thereby addressing both insulin resistance and beta-cell dysfunction. Imextor 500 is prescribed as an adjunct to diet and exercise to achieve optimal glycemic control in adult patients inadequately controlled on monotherapy or combination therapy. Clinical studies have demonstrated its efficacy in lowering HbA1c levels with a favorable safety profile, exhibiting minimal risk of hypoglycemia when used as monotherapy. The recommended dosage is one tablet taken orally twice daily, with or without food, as directed by a healthcare professional. Common adverse effects may include gastrointestinal disturbances such as nausea and diarrhea, which are generally mild and transient. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended during therapy. Imextor 500 should be used under medical supervision to optimize diabetes management and reduce the risk of long-term complications.